Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells $309,267.20 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $43.93, for a total value of $309,267.20. Following the transaction, the chief executive officer owned 39,120 shares of the company’s stock, valued at $1,718,541.60. This trade represents a 15.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.02, for a total value of $232,425.60.
• On Monday, November 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.56, for a total transaction of $235,276.80.
• On Thursday, November 13th, Jack Bendheim sold 8,801 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.47, for a total transaction of $391,380.47.
• On Wednesday, November 12th, Jack Bendheim sold 21,536 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.23, for a total transaction of $974,073.28.
• On Monday, November 10th, Jack Bendheim sold 38,303 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.29, for a total transaction of $1,734,742.87.
• On Friday, November 7th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $42.86, for a total transaction of $150,867.20.
• On Tuesday, November 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $43.10, for a total transaction of $151,712.00.
• On Thursday, October 30th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.07, for a total value of $144,566.40.
• On Tuesday, October 28th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.56, for a total value of $146,291.20.
• On Thursday, October 23rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.18, for a total value of $141,433.60.

Phibro Animal Health Stock Down 2.8%

PAHC opened at $42.00 on Friday. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. The company has a market capitalization of $1.70 billion, a PE ratio of 35.59, a P/E/G ratio of 1.24 and a beta of 0.81. The stock’s fifty day moving average is $40.99 and its 200-day moving average is $33.37. Phibro Animal Health Corporation has a one year low of $16.16 and a one year high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The firm had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, equities analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th will be paid a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, November 26th. This represents a $0.48 annualized dividend and a yield of 1.1%. Phibro Animal Health’s dividend payout ratio is currently 28.92%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Bank of America lifted their target price on Phibro Animal Health from $19.00 to $27.00 and gave the stock an “underperform” rating in a report on Friday, August 29th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday. Morgan Stanley set a $34.00 price target on Phibro Animal Health in a research report on Thursday, August 28th. Finally, JPMorgan Chase & Co. lifted their price target on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $31.40.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. National Bank of Canada FI purchased a new stake in Phibro Animal Health in the 1st quarter worth about $30,000. Financial Management Professionals Inc. purchased a new stake in shares of Phibro Animal Health in the second quarter worth approximately $32,000. Hughes Financial Services LLC acquired a new stake in shares of Phibro Animal Health during the third quarter worth approximately $40,000. iSAM Funds UK Ltd acquired a new stake in shares of Phibro Animal Health during the third quarter worth approximately $61,000. Finally, EverSource Wealth Advisors LLC grew its position in Phibro Animal Health by 7,671.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after purchasing an additional 2,685 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.